Meningococcal Vaccine Menactra

Meningococcal Vaccine Menactra is a quadrivalent meningococcal conjugate vaccine designed for active immunization against Neisseria meningitidis serogroups A, C, Y, and W-135. It is recommended for routine vaccination, travel immunization, and outbreak control in adolescents, adults, and high-risk populations.

Menactra works by stimulating the body’s immune system to produce protective antibodies against multiple meningococcal serogroups, reducing the risk of invasive meningococcal disease. The vaccine is supplied for use only by qualified healthcare professionals, ensuring safe and effective administration.

The meningococcal vaccine Menactra is a trusted meningococcal immunization product commonly used in hospitals, clinics, and public health programs. This product is suitable for regulated domestic and international vaccination initiatives and provides reliable protection against meningococcal infections.

Product Features

• Protects against meningococcal serogroups A, C, Y, and W-135
• Conjugate vaccine for enhanced and longer-lasting immunity
• Widely used in routine and travel vaccination programs
• Suitable for adolescents and adults (age as per guidelines)
• WHO-recommended meningococcal vaccine
• Supplied in ready-to-use injectable form

How It Helps

• Protects against meningococcal disease caused by serogroups A, C, Y, and W-135
• Provides long-lasting immunity through conjugate technology
• Reduces risk of invasive meningococcal infections in high-risk populations
• Supports routine, travel, and outbreak vaccination programs